These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38107670)

  • 1. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
    Russo F; Galluzzo M; Stingeni L; Persechino S; Zichichi L; Conti A; Giofrè C; Dini V; Vispi M; Atzori L; Cattaneo A; Parodi A; Bardazzi F; Stinco G; Dapavo P; Girolomoni G; Musumeci ML; Papini M; Venturini M; Dastoli S; Di Nuzzo S; Fargnoli MC; Pagnanelli G; Bernardini N; Gambini DM; Malagoli P; Mazzatenta C; Peris K; Zalaudek I; Fabbrocini G; Loconsole F; Vassallo C; Pietroleonardo L; Prignano F; Franchi C; Offidani AM; Bonifati C; Di Lernia V; Gigante G; Bartezaghi MS; Franchi M; Ursoleo P; Aloisi E
    Clin Cosmet Investig Dermatol; 2023; 16():3561-3574. PubMed ID: 38107670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
    Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
    Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
    Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea.
    Kim BS; Kim DH; Shin BS; Lee ES; Jo SJ; Bang CH; Yun Y; Choe YB
    Ther Adv Chronic Dis; 2024; 15():20406223241230180. PubMed ID: 38415046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
    Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
    Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
    Chicharro P; Llamas-Velasco M; Armesto S; Herrera Acosta E; Vidal D; Vilarrasa E; Rivera-Diaz R; De-la-Cueva P; Martorell-Calatayud A; Ballescà F; Belinchon I; Carretero G; Rodriguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés Rodríguez O; Feltes R; Riera-Monroig J; Dauden E
    Dermatol Ther; 2022 Dec; 35(12):e15929. PubMed ID: 36223184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
    Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
    Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.
    Talamonti M; Russo F; Malara G; Hansel K; Papini M; Cattaneo A; Parodi A; Chiricozzi A; Malagoli P; Bardazzi F; Brazzelli V; Dapavo P; Gisondi P; Zane C; Potenza C; Cantoresi F; Fargnoli MC; Trevisini S; Brianti P; Pescitelli L; Gigante G; Bartezaghi M; Caputo L; Aloisi E; Costanzo A;
    Clin Cosmet Investig Dermatol; 2023; 16():847-852. PubMed ID: 37033782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.
    Foley P; Tsai TF; Rodins K; Hamadah IR; Ammoury A; Dayem HA; Abdallah M; Crowe S; Haas S; Pournara E; Jagiello P; Huang YH
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):511-527. PubMed ID: 35038128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
    Papp KA; Gooderham M; Dei-Cas I; LopezTello A; Garcia-Rodriguez JC; Taveras CY; Rousselin AH; Lavieri A; Maiolino M; Quintero DGV; Rihakova L; Salibe M; Pertuz W
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):269-283. PubMed ID: 36496547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.
    Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1351-1365. PubMed ID: 35551619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.